Gemphire Therapeutics Inc. (GEMP) Surged to $10.11

June 29, 2018 - By Sergio Grout

Gemphire Therapeutics Inc. (NASDAQ:GEMP) trading at $10.11 after increase. The move was reported on Jun, 29 by Barchart.com. The company has $143.89M market cap. At $10.72 PT, the company’s valuation could be $8.63 million more.

On August, 13 Gemphire Therapeutics Inc. (NASDAQ:GEMP)’s earnings report is awaited by WallStreet, Faxor reports. The EPS diference is $0.17 or 22.97 % up from last years number. Previous year: $-0.74; Analysts forcast: $-0.57. Wall Street now predicts -1.72 % EPS growth despite Gemphire Therapeutics Inc. previous quarter’s EPS of $-0.58.

For more Gemphire Therapeutics Inc. (NASDAQ:GEMP) news published recently go to: Benzinga.com, Streetinsider.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “5 Stocks Moving In Thursday’s After-Hours Session” published on June 21, 2018, “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” on June 28, 2018, “Jefferies sees more headroom for Gemphire, up 97%” with a publish date: June 29, 2018, “Mid-Morning Market Update: Markets Open Higher; Constellation Brands Earnings Miss Estimates” and the last “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with publication date: June 29, 2018.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis .The company has $143.89 million market cap. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH.Last it reported negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: